EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents

Zhiqiang Sun, Xuewen Zhang, Zean Zhao iD, Xiaoxun Li iD, Jianxin Pang iD, Jianjun Chen iD

Journal of Medicinal Chemistry · 28.11.2024 · 67 (22) · 19966-19987

DOI: 10.1021/acs.jmedchem.4c01260 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.11.2024. Verfasst von Zhiqiang Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutic…. Hauptthemen laut MEDLINE: Hyperuricemia, Xanthine Oxidase, Organic Anion Transporters. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 128 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, China Postdoctoral Science Foundation, Southern Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increased biosynthesis or underexcretion of uric acid (UA or urate) in the body ultimately leads to the development of hyperuricemia. Epidemiological studies indicate that hyperuricemia is closely associated with the occurrence of various diseases such as gout and cardiovascular diseases. Currently, the first-line therapeutic medications used to reduce UA levels primarily include xanthine oxidase (XO) inhibitors, which limit UA production, and urate transporter 1 (URAT1) inhibitors, which decrease urate reabsorption and enhance urate excretion. Despite significant progress in urate-lowering therapies, long-term use of these drugs can cause hepatorenal toxicity as well as cardiovascular complications. Therefore, there is an urgent need for novel anti-hyperuricemic agents with better efficacy and lower toxicity. This perspective mainly focuses on the current research progress and design strategy of anti-hyperuricemic agents, particularly those targeting XO and URAT1. It is our hope that this perspective will provide insights into the challenges and opportunities for anti-hyperuricemic drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperuricemiaXanthine OxidaseOrganic Anion TransportersHumansOrganic Cation Transport ProteinsAnimalsUric Acid

Substanzen

Xanthine OxidaseOrganic Anion TransportersSLC22A12 protein, humanOrganic Cation Transport ProteinsUric Acid

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
  • Chengdu Easton Biopharmaceuticals Co., Ltd., Chengdu 611731, China.

ORCID-Profile: Zean Zhao, Xiaoxun Li, Jianxin Pang, Jianjun Chen

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • China Postdoctoral Science Foundation
  • Southern Medical University

Zitieren

APA

Sun, Z., Zhang, X., Zhao, Z., Li, X., Pang, J., & Chen, J. (2024). Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents. Journal of Medicinal Chemistry, 67(22), 19966-19987. https://doi.org/10.1021/acs.jmedchem.4c01260

Vancouver

Sun Z, Zhang X, Zhao Z, Li X, Pang J, Chen J. Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents. Journal of Medicinal Chemistry. 2024;67(22):19966-19987. doi:10.1021/acs.jmedchem.4c01260

BibTeX
@article{Sun2024,
  author = {Sun, Zhiqiang and Zhang, Xuewen and Zhao, Zean and Li, Xiaoxun and Pang, Jianxin and Chen, Jianjun},
  title = {Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {22},
  pages = {19966--19987},
  doi = {10.1021/acs.jmedchem.4c01260}
}
Kostenlos starten →